HomeInsightsStock Comparison

Alembic Pharmaceuticals Ltd vs Themis Medicare Ltd Stock Comparison

Alembic Pharmaceuticals Ltd vs Themis Medicare Ltd Stock Comparison

Last Updated on: Jun 05, 2025

Key Highlights

  • The Latest Trading Price of Alembic Pharmaceuticals Ltd is ₹ 972.85 as of 05 Jun 15:30.
  • The P/E Ratio of Alembic Pharmaceuticals Ltd changed from 12.1 on March 2020 to 31.4 on March 2024 . This represents a CAGR of 21.01% over 5 yearsThe P/E Ratio of Themis Medicare Ltd changed from 8.9 on March 2020 to 46.3 on March 2024 . This represents a CAGR of 39.07% over 5 years.
  • The Market Cap of Alembic Pharmaceuticals Ltd changed from ₹ 10059 crore on March 2020 to ₹ 19309 crore on March 2024 . This represents a CAGR of 13.93% over 5 yearsThe Market Cap of Themis Medicare Ltd changed from ₹ 220.51 crore on March 2020 to ₹ 2015 crore on March 2024 . This represents a CAGR of 55.67% over 5 years.
  • The revenue of Alembic Pharmaceuticals Ltd for the Mar '25 is ₹ 1783 crore as compare to the Dec '24 revenue of ₹ 1702 crore. This represent the growth of 4.77% The revenue of Themis Medicare Ltd for the Mar '25 is ₹ 73.25 crore as compare to the Dec '24 revenue of ₹ 94.83 crore. This represent the decline of -22.76%.
  • The ebitda of Alembic Pharmaceuticals Ltd for the Mar '25 is ₹ 285.46 crore as compare to the Dec '24 ebitda of ₹ 270.08 crore. This represent the growth of 5.69% The ebitda of Themis Medicare Ltd for the Mar '25 is ₹ -6.14 crore as compare to the Dec '24 ebitda of ₹ 6.99 crore. This represent the decline of -187%.
  • The net profit of Alembic Pharmaceuticals Ltd changed from ₹ 120.6 crore to ₹ 156.63 crore over 8 quarters. This represents a CAGR of 13.96% The net profit of Themis Medicare Ltd changed from ₹ 18.19 crore to ₹ -9.66 crore over 8 quarters. This represents a CAGR of NaN% .
  • The Dividend Payout of Alembic Pharmaceuticals Ltd changed from 19.45 % on March 2020 to 32.44 % on March 2024 . This represents a CAGR of 10.77% over 5 yearsThe Dividend Payout of Themis Medicare Ltd changed from 10.11 % on March 2020 to 18.59 % on March 2024 . This represents a CAGR of 12.96% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Alembic Pharmaceuticals Ltd

  • Alembic Pharmaceuticals Limited manufactures and markets generic pharmaceutical products all over the world.
  • The company's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. The company is one of the leaders in branded generics in India. Alembic Pharmaceuticals Limited was incorporated on June 16, 2010 as a wholly owned subsidiary of Alembic Limited.
  • The company is engaged in pharmaceuticals business.
  • As per the Scheme of Arrangement, the 'Pharmaceutical Undertaking' of Alembic Limited got demerged and transferred to the Company with effect from April 1, 2010. In April 2011, the company ceased to be a subsidiary of Alembic Ltd consequent to the allotment of 13,35,15,914 equity shares of Rs 2 each to the shareholders of Alembic Ltd as per the scheme of arrangement.

About Themis Medicare Ltd

  • Themis Medicare Limited was formerly incorporated as 'Themis Chemicals Limited' in 1969.
  • The Company was originally promoted by Chemosyn and Medimpex but was taken over by a Group consisting of Shantibhai D Patel and K T Lakdawala who also have interests in Andhra Synthetics and Antibiotics, which was merged with Artemis Pharmaceuticals in April, 1993.
  • Thereafter, the name of the Company was changed to Themis Medicare Limited in 2001.
  • The Group is principally engaged in the activities pertaining to manufacturing of pharmaceutical products, especially in Formulation and API activity. In Mar.'95, the company came out with a public issue equity shares (premium : Rs 110) to finance the expansion-cum-modernisation of its synthetic bulk drug plant at Vapi, the setting up of a formulation unit at Lilora, Baroda as backward integration and to augment long-term working capital.

Alembic Pharmaceuticals Ltd News Hub

News

Alembic Pharma slips as USFDA issues four observations for Panelav API facility

According to a regulatory filing, the USFDA conducted an unannounced and routine current g...

Read more

02 Jun 2025 11:58

News

Alembic Pharma receives USFDA final approval for Bosutinib tablets

Bosutinib tablets are indicated for the treatment of adult patients with chronic, accelera...

Read more

30 May 2025 15:42

News

Alembic Pharma receives USFDA nod for Amlodipine and Atorvastatin Tablets

Amlodipine and Atorvastatin tablets are a combination medication used to treat high blood ...

Read more

23 May 2025 15:08

News

Alembic Pharmaceuticals receives USFDA approval for Rivaroxaban Tablets

Alembic Pharmaceuticals (Alembic) today announced that it has received final approval from...

Read more

15 May 2025 14:14

News

Alembic Pharma rises on USFDA approval for Rivaroxaban Tablets

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD)...

Read more

15 May 2025 16:36

News

Board of Alembic Pharmaceuticals recommends final dividend

Alembic Pharmaceuticals announced that the Board of Directors of the Company at its meetin...

Read more

06 May 2025 14:39

Themis Medicare Ltd News Hub

News

Board of Themis Medicare recommends final dividend

Themis Medicare announced that the Board of Directors of the Company at its meeting held o...

Read more

21 May 2025 11:37

News

Themis Medicare to declare Quarterly Results

Themis Medicare will hold a meeting of the Board of Directors of the Company on 20 May 202...

Read more

16 May 2025 16:53

News

Themis Medicare to discuss results

Themis Medicare will hold a meeting of the Board of Directors of the Company on 14 Februar...

Read more

11 Feb 2025 10:53

News

Themis Medicare to discuss results

Themis Medicare will hold a meeting of the Board of Directors of the Company on 25 October...

Read more

19 Oct 2024 10:22

News

Themis Medicare to hold board meeting

Themis Medicare will hold a meeting of the Board of Directors of the Company on 26 July 20...

Read more

17 Jul 2024 09:49

News

Board of Themis Medicare recommends final dividend

Themis Medicare announced that the Board of Directors of the Company at its meeting held o...

Read more

15 May 2024 10:44

SWOT Analysis Of Alembic Pharmaceuticals Ltd

Strength

1

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Themis Medicare Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Alembic Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Themis Medicare Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Alembic Pharmaceuticals Ltd and Themis Medicare Ltd

Which company has a larger market capitalization, Alembic Pharmaceuticals Ltd or Themis Medicare Ltd?

Market cap of Alembic Pharmaceuticals Ltd is 19,122 Cr while Market cap of Themis Medicare Ltd is 1,276 Cr

What are the key factors driving the stock performance of Alembic Pharmaceuticals Ltd and Themis Medicare Ltd?

The stock performance of Alembic Pharmaceuticals Ltd and Themis Medicare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alembic Pharmaceuticals Ltd and Themis Medicare Ltd?

As of June 5, 2025, the Alembic Pharmaceuticals Ltd stock price is INR ₹972.85. On the other hand, Themis Medicare Ltd stock price is INR ₹138.7.

How do dividend payouts of Alembic Pharmaceuticals Ltd and Themis Medicare Ltd compare?

To compare the dividend payouts of Alembic Pharmaceuticals Ltd and Themis Medicare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions